Literature DB >> 20963473

Prognostic significance of claudin expression changes in breast cancer with regional lymph node metastasis.

A M Szasz1, A M Tokes, M Micsinai, T Krenacs, Cs Jakab, L Lukacs, Zs Nemeth, Zs Baranyai, K Dede, L Madaras, J Kulka.   

Abstract

Adherent and tight junction molecules have been described to contribute to carcinogenesis and tumor progression. Additionally, the group of claudin-low tumors have recently been identified as a molecular subgroup of breast carcinoma. In our study, we examined the expression pattern of claudins, beta-catenin and E-cadherin in invasive ductal (IDCs) and lobular (ILCs) carcinomas and their corresponding lymph node metastases (LNMs). Tissue microarrays of 97 breast samples (60 invasive ductal carcinomas, 37 invasive lobular carcinomas) and their corresponding LNMs have been analyzed immunohistochemically for claudin-1, -2, -3, -4, -5, -7, beta-catenin and E-cadherin expression. The stained slides were digitalized with a slide scanner and the reactions were evaluated semiquantitatively. When compared to LNMs, in the IDC group beta-catenin and claudin-2, -3, -4 and -7 protein expression showed different pattern while claudin-1, -2, -3, -4 and -7 were differently expressed in the ILC group. Lymph node metastases developed a notable increase of claudin-5 expression in both groups. Decrease or loss of claudin-1 and expression of claudin-4 in lymph node metastases correlated with reduced disease-free survival in our patients. According to our observations, the expression of epithelial junctional molecules, especially claudins, is different in primary breast carcinomas compared to their lymph node metastases as demonstrated by immunohistochemistry. Loss of claudin junctional molecules might contribute to tumor progression, and certain claudin expression pattern might be of prognostic relevance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20963473     DOI: 10.1007/s10585-010-9357-5

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  53 in total

1.  Nuclear beta-catenin in basal cell carcinoma correlates with increased proliferation.

Authors:  G Saldanha; V Ghura; L Potter; A Fletcher
Journal:  Br J Dermatol       Date:  2004-07       Impact factor: 9.302

2.  Claudin expression in breast tumors.

Authors:  Janina Kulka; Anna-Maria Tökés
Journal:  Hum Pathol       Date:  2005-07       Impact factor: 3.466

3.  Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast.

Authors:  Scott L Kominsky; Pedram Argani; Dorian Korz; Ella Evron; Venu Raman; Elizabeth Garrett; Alan Rein; Guido Sauter; Olli-P Kallioniemi; Saraswati Sukumar
Journal:  Oncogene       Date:  2003-04-03       Impact factor: 9.867

Review 4.  Molecular requirements for epithelial-mesenchymal transition during tumor progression.

Authors:  Margit A Huber; Norbert Kraut; Hartmut Beug
Journal:  Curr Opin Cell Biol       Date:  2005-10       Impact factor: 8.382

Review 5.  Epithelial-mesenchymal transitions in cancer progression.

Authors:  C Birchmeier; W Birchmeier; B Brand-Saberi
Journal:  Acta Anat (Basel)       Date:  1996

6.  Tissue microarrays: one size does not fit all.

Authors:  Jeanette E Eckel-Passow; Christine M Lohse; Yuri Sheinin; Paul L Crispen; Christopher J Krco; Eugene D Kwon
Journal:  Diagn Pathol       Date:  2010-07-07       Impact factor: 2.644

7.  Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma.

Authors:  Yu-Chih Chao; Szu-Hua Pan; Shuenn-Chen Yang; Sung-Liang Yu; Ting-Fang Che; Chung-Wu Lin; Mu-Shiun Tsai; Gee-Chen Chang; Che-Hsiang Wu; Yi-Ying Wu; Yung-Chie Lee; Tse-Ming Hong; Pan-Chyr Yang
Journal:  Am J Respir Crit Care Med       Date:  2008-09-11       Impact factor: 21.405

8.  E-cadherin binding prevents beta-catenin nuclear localization and beta-catenin/LEF-1-mediated transactivation.

Authors:  S Orsulic; O Huber; H Aberle; S Arnold; R Kemler
Journal:  J Cell Sci       Date:  1999-04       Impact factor: 5.285

9.  Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors.

Authors:  Jason I Herschkowitz; Karl Simin; Victor J Weigman; Igor Mikaelian; Jerry Usary; Zhiyuan Hu; Karen E Rasmussen; Laundette P Jones; Shahin Assefnia; Subhashini Chandrasekharan; Michael G Backlund; Yuzhi Yin; Andrey I Khramtsov; Roy Bastein; John Quackenbush; Robert I Glazer; Powel H Brown; Jeffrey E Green; Levy Kopelovich; Priscilla A Furth; Juan P Palazzo; Olufunmilayo I Olopade; Philip S Bernard; Gary A Churchill; Terry Van Dyke; Charles M Perou
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

10.  Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study.

Authors:  Anna-Mária Tokés; Janina Kulka; Sándor Paku; Agnes Szik; Csilla Páska; Pál Kaposi Novák; László Szilák; András Kiss; Krisztina Bögi; Zsuzsa Schaff
Journal:  Breast Cancer Res       Date:  2005-01-31       Impact factor: 6.466

View more
  25 in total

1.  Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytes.

Authors:  Sébastien Tabariès; Fanny Dupuy; Zhifeng Dong; Anie Monast; Matthew G Annis; Jonathan Spicer; Lorenzo E Ferri; Atilla Omeroglu; Mark Basik; Eitan Amir; Mark Clemons; Peter M Siegel
Journal:  Mol Cell Biol       Date:  2012-05-29       Impact factor: 4.272

2.  Correlation of NGX6 expression with clinicopathologic features and prognosis in colon cancer.

Authors:  Jidong Xiao; Yuanquan Zhou; Bo Liu
Journal:  Int J Clin Exp Med       Date:  2015-08-15

3.  IQGAP1 controls tight junction formation through differential regulation of claudin recruitment.

Authors:  Barbara E Tanos; Andres E Perez Bay; Susana Salvarezza; Igor Vivanco; Ingo Mellinghoff; Mahasin Osman; David B Sacks; Enrique Rodriguez-Boulan
Journal:  J Cell Sci       Date:  2015-01-14       Impact factor: 5.285

4.  Epithelial-mesenchymal transition markers in lymph node metastases and primary breast tumors - relation to dissemination and proliferation.

Authors:  Aleksandra Markiewicz; Marzena Wełnicka-Jaśkiewicz; Barbara Seroczyńska; Jarosław Skokowski; Hanna Majewska; Jolanta Szade; Anna J Żaczek
Journal:  Am J Transl Res       Date:  2014-11-22       Impact factor: 4.060

5.  Expression of tight junction molecules in breast carcinomas analysed by array PCR and immunohistochemistry.

Authors:  Anna-Mária Tőkés; Attila Marcell Szász; Eva Juhász; Zsuzsa Schaff; László Harsányi; István Arthur Molnár; Zsolt Baranyai; István Besznyák; Attila Zaránd; Ferenc Salamon; Janina Kulka
Journal:  Pathol Oncol Res       Date:  2011-12-23       Impact factor: 3.201

6.  Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences.

Authors:  Siker Kimbung; Anikó Kovács; Pär-Ola Bendahl; Per Malmström; Mårten Fernö; Thomas Hatschek; Ingrid Hedenfalk
Journal:  Mol Oncol       Date:  2013-10-14       Impact factor: 6.603

7.  Strong claudin 5 expression is a poor prognostic sign in pancreatic adenocarcinoma.

Authors:  Ylermi Soini; M Eskelinen; P Juvonen; V Kärjä; K M Haapasaari; A Saarela; P Karihtala
Journal:  Tumour Biol       Date:  2014-02-12

8.  Claudin-1 Protein Expression Is a Good Prognostic Factor in Non-Small Cell Lung Cancer, but only in Squamous Cell Carcinoma Cases.

Authors:  Judit Moldvay; Katalin Fábián; Márta Jäckel; Zsuzsanna Németh; Krisztina Bogos; József Furák; László Tiszlavicz; János Fillinger; Balázs Döme; Zsuzsa Schaff
Journal:  Pathol Oncol Res       Date:  2016-09-29       Impact factor: 3.201

9.  Overexpression of Claudin-1 is Associated with Advanced Clinical Stage and Invasive Pathologic Characteristics of Oral Squamous Cell Carcinoma.

Authors:  Kraisorn Sappayatosok; Ekarat Phattarataratip
Journal:  Head Neck Pathol       Date:  2014-07-31

10.  Claudins play a role in normal and tumor cell motility.

Authors:  Patricia G Webb; Monique A Spillman; Heidi K Baumgartner
Journal:  BMC Cell Biol       Date:  2013-03-23       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.